Sobi maintains patient engagement position in Corporate Reputation of Pharma Report
Sobi held its No. 2 ranking* for the second year in a row in the newly published, independent Corporate Reputation of Pharma Report 2025/2026 – Global Edition.
The Global Edition reflects feedback from more than 2,400 patient groups representing 36 million patients and assesses how pharmaceutical companies are perceived across all disease areas.
PatientView publishes two related but distinct reports each year: a Global Edition, covering all disease areas, and a separate Rare Disease Edition, focusing specifically on companies specialised in rare conditions. The Rare Disease Edition of the report will be published later this year. In the previous Rare Disease Edition (2024/2025), Sobi ranked No. 1 worldwide.
Together, the global and the rare disease editions underline Sobi’s consistent performance over time and our ability to build trusted relationships both within rare diseases and across the wider pharmaceutical landscape, independent of therapy area.
“Being ranked No. 2 again, for two years in row, by the wider patient group audience we work with is a powerful signal of trust. This feedback motivates us to continue learning from the patient community and to further strengthen how we engage and make a difference for the people we serve”, says Giampiero Marra, VP, Head of Global Patient Engagement & Patient Communication at Sobi.
Over the past year, the number of patient groups recognising and collaborating with Sobi has increased, from 213 to 225 groups familiar with Sobi, and from 92 to 113 groups working with us. This growth reflects how our partnerships, visibility and long-term commitment continue to strengthen across the global patient community.
Strong performance across key areas
In the global report, Sobi performed 2nd across multiple categories*:
- Patient centricity
- Patient information
- Patient safety
- Transparency of pricing
- Integrity
- Patient group relationships
- Services beyond the pill
Our commitment
Through Unite4Rare, our global patient‑engagement framework, we continue to work side by side with patient groups to co‑create solutions and improve everyday life for people living with rare conditions. Unite4Rare is built on four commitments: connect, nurture, collaborate and innovate, ensuring engagement is meaningful, ethical and forward‑looking. Each year, a Unite4Rare Global Council, made up of patient‑organisation representatives across therapy areas, reviews progress and helps shape future priorities together with Sobi.
Learn more about Sobi’s commitment to patients:
The annual Corporate Reputation of Pharma Report, conducted by PatientView, gives patient groups the opportunity to independently evaluate the pharmaceutical industry and benchmark companies against their peers. The surveys are carried out by the UK based research, publishing and consultancy group, founded on the belief that the views of patients should be central to healthcare decision making.
*As rated by patient groups working with Sobi
Source: https://www.patient-view.com/
We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases.
Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care.
We contribute to societies by improving access to treatment of rare diseases.
Here we present our most recent press releases, stories, news articles, and images.
Find out more about our business and financial performance.
Every day, we work actively to find better ways to understand and meet patient needs.
- About
- Therapeutic areas
- Medicines
- Sustainability
- News & Stories
- Investors
- Careers
- English
- Swedish